A Phase I, Open-label, Single-dose, Sequential Dose Group Study of Orally Administered M5049 Tablet Formulation in Healthy Japanese and Caucasian Participants to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Latest Information Update: 28 Dec 2022
At a glance
- Drugs Enpatoran (Primary)
- Indications COVID-19 pneumonia; Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck KGaA
- 14 Nov 2022 Results presented at the ACR Convergence 2022
- 17 Sep 2021 Status changed from recruiting to completed.
- 15 Jul 2021 Planned End Date changed from 23 Jul 2021 to 9 Sep 2021.